Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexacerfont in Generalized Anxiety Disorder
NCT00481325Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pexacerfont in generalized anxiety disorder (GAD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Hamilton Anxiety Rating Scale at 8 weeks. Started Jul 2007; status: completed.
02
Drugs
pexacerfont
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00481325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481325.